The histone deacetylase inhibitor romidepsin is a potential therapeutic for metastatic osteosarcoma

被引：0
作者：
Seiden, Emily E.
Richardson, Spencer M.
Ramnath, Shrey
Whiteside, Tia
Coy, Kathryn L.
Sinn, Anthony L.
Capitano, Maegan L.
Pollok, Karen E.
Collier, Chris D.
Greenfield, Ed M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7554
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Therapeutic potential of selective histone deacetylase 3 inhibition
    Zhang, Lihui
    Chen, Yiming
    Jiang, Qixiao
    Song, Weiguo
    Zhang, Lei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 162 : 534 - 542
  • [42] Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells
    Roh, MS
    Kim, CW
    Park, BS
    Kim, GC
    Jeong, JH
    Kwon, HC
    Suh, DJ
    Cho, KH
    Yee, SB
    Yoo, YH
    APOPTOSIS, 2004, 9 (05) : 583 - 589
  • [43] The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin
    Luke A. Wittenburg
    Liam Bisson
    Barbara J. Rose
    Christopher Korch
    Douglas H. Thamm
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 83 - 92
  • [44] The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin
    Wittenburg, Luke A.
    Bisson, Liam
    Rose, Barbara J.
    Korch, Christopher
    Thamm, Douglas H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 83 - 92
  • [45] Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells
    M. S. Roh
    C. W. Kim
    B. S. Park
    G. C. Kim
    J. H. Jeong
    H. C. Kwon
    D. J. Suh
    K. H. Cho
    S.-B. Yee
    Y. H. Yoo
    Apoptosis, 2004, 9 : 583 - 589
  • [46] Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia
    Odenike, Olatoyosi M.
    Alkan, Serhan
    Sher, Dorie
    Godwin, John E.
    Huo, Dezheng
    Brandt, Stephen J.
    Green, Margaret
    Xie, Jingping
    Zhang, Yariming
    Vesole, David H.
    Stiff, Patrick
    Wright, John
    Larson, Richard A.
    Stock, Wendy
    CLINICAL CANCER RESEARCH, 2008, 14 (21) : 7095 - 7101
  • [47] Effects of the histone deacetylase inhibitor romidepsin in lymphoma B-cells and BCL6 regulation
    Cortiguera, M. G.
    Garcia-Gaipo, L.
    Batlle-Lopez, A.
    Delgado, M. D.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S106 - S106
  • [48] Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma
    Woyach, Jennifer A.
    Kloos, Richard T.
    Ringel, Matthew D.
    Arbogast, Daria
    Collamore, Minden
    Zwiebel, James A.
    Grever, Michael
    Villalona-Calero, Miguel
    Shah, Manisha H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (01) : 164 - 170
  • [49] Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors
    Shah, Manisha H.
    Binkley, Philip
    Chan, Kenneth
    Xiao, Jim
    Arbogast, Daria
    Collamore, Minden
    Farra, Yasser
    Young, Donn
    Grever, Michael
    CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3997 - 4003
  • [50] A NOVEL THERAPEUTIC APPROACH USING HISTONE DEACETYLASE INHIBITOR ROMIDEPSIN (RM) AND NATURAL KILLER CELLS IN THE TREATMENT OF HIGH RISK LEUKEMIA/LYMPHOMAS(HRLL): POTENTIAL FOR TARGETED ADOPTIVE CELLULAR IMMUNOTHERAPY
    Satwani, P.
    Bavishi, S.
    Saha, A.
    Segal, L.
    Cairo, M.
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (09) : S90 - S91
12345